ldn and crohns
- From: davizona <daveinohio@xxxxxxxxx>
- Date: Wed, 20 May 2009 06:35:51 -0700 (PDT)
Low-dose naltrexone therapy improves active Crohn's disease.Smith JP,
Stock H, Bingaman S, Mauger D, Rogosnitzky M, Zagon IS.
Department of Medicine, Pennsylvania State University College of
Medicine, Hershey, Pennsylvania 17033, USA.
OBJECTIVES: Endogenous opioids and opioid antagonists have been shown
to play a role in healing and repair of tissues. In an open-labeled
pilot prospective trial, the safety and efficacy of low-dose
naltrexone (LDN), an opioid antagonist, were tested in patients with
active Crohn's disease. METHODS: Eligible subjects with histologically
and endoscopically confirmed active Crohn's disease activity index
(CDAI) score of 220-450 were enrolled in a study using 4.5 mg
naltrexone/day. Infliximab was not allowed for a minimum of 8 wk prior
to study initiation. Other therapy for Crohn's disease that was at a
stable dose for 4 wk prior to enrollment was continued at the same
doses. Patients completed the inflammatory bowel disease questionnaire
(IBDQ) and the short-form (SF-36) quality of life surveys and CDAI
scores were assessed pretreatment, every 4 wk on therapy and 4 wk
after completion of the study drug. Drug was administered by mouth
each evening for a 12-wk period. RESULTS: Seventeen patients with a
mean CDAI score of 356 +/- 27 were enrolled. CDAI scores decreased
significantly (P= 0.01) with LDN, and remained lower than baseline 4
wk after completing therapy. Eighty-nine percent of patients exhibited
a response to therapy and 67% achieved a remission (P < 0.001).
Improvement was recorded in both quality of life surveys with LDN
compared with baseline. No laboratory abnormalities were noted. The
most common side effect was sleep disturbances, occurring in seven
patients. CONCLUSIONS: LDN therapy appears effective and safe in
subjects with active Crohn's disease. Further studies are needed to
explore the use of this compound.
PMID: 17222320 [PubMed - indexed for MEDLINE]
Related articles
Remission in patients with Crohn's disease is associated with
improvement in employment and quality of life and a decrease in
hospitalizations and surgeries. Am J Gastroenterol. 2004 Jan; 99(1):
91-6.
[Am J Gastroenterol. 2004]
Infliximab heals intestinal inflammatory lesions and restores growth
in children with Crohn's disease. Dig Liver Dis. 2004 May; 36(5):
342-7.
[Dig Liver Dis. 2004]
Treatment of perianal fistulas in Crohn's disease by local injection
of antibody to TNF-alpha accounts for a favourable clinical response
in selected cases: a pilot study. Scand J Gastroenterol. 2006 Sep; 41
(9):1064-72.
[Scand J Gastroenterol. 2006]
ReviewTumor necrosis factor-alpha antibody for maintenance of
remission in Crohn's disease. Cochrane Database Syst Rev. 2008 Jan 23;
(1):CD006893. Epub 2008 Jan 23.
[Cochrane Database Syst Rev. 2008]
ReviewNatalizumab for induction of remission in Crohn's disease.
Cochrane Database Syst Rev. 2007 Jan 24; (1):CD006097. Epub 2007 Jan
24.
[Cochrane Database Syst Rev. 2007]
» See reviews... | » See all...
.
- Prev by Date: ldn and autism
- Next by Date: ldn and autoimmune
- Previous by thread: ldn and autism
- Next by thread: ldn and autoimmune
- Index(es):
Relevant Pages
|
Loading
